Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form

ABSTRACT

Despite comprehensive and stringent phases of clinical trials and surveillance efforts, unexpected and serious adverse drug reactions (ADRs) repeatedly occur after the drug is marketed. ADR reporting is an important aspect of an efficient and effective pharmacovigilance program. Although Medwatch, Yellow Card, CDSCO form, etc. are the protocol forms of ADR collection and reports, a number of countries design and use their respective ADR forms. This review compares similarities and dissimilarities of 13 ADR forms of countries representing their geographical location. This study extracted 73 data elements mentioned in 13 different ADR forms. Only 13 elements were common. An ADR form of Malaysia and Canada covers the highest number of data 43, while Brazil falls to the opposite end with a number of 17 data elements in lieu with the Generic ADR Form. The result of this review highlights 58 data elements of the proposed generic ADR form which ensures that requisite reporting information essential for correct causality assessment of ADRs are included. The proposed “Generic ADR form” could be adopted worldwide mandatorily for reporting any/all ADRs associated with marketed drugs.

KEYWORDS

• Causality assessment
• generic form
• pharmacovigilance

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.4103/0976-500X.99417Copy

RELATED ARTICLES

Matched on volume, issue, section and article type within J Pharmacol. Pharmacother..

• Article · VOLUME 3, ISSUE 2A review of antihistamines used during pregnancySumit Kar, Ajay Krishnan, Preetha K., Atul Mohankar · pp. 105–108Mini ReviewSame type: ArticleVolume 3
• Article · VOLUME 3, ISSUE 1Iptakalim: A novel multi-utility potassium channel opener(Kir6.1s) (Kir6.1s), regulatory sulphonylurea subunits (SUR).[3] IPT shows high selectivity for cardiac KATP (SUR2A/Kir6.2), vascular KATP (SUR2B/Kir6.1 or SUR6B/Kir6.2). Because · pp. 12–14Mini ReviewSame type: ArticleVolume 3
• Article · VOLUME 3, ISSUE 2Ulipristal acetate, a progesterone receptor modulator for emergency contraceptionShilpa P. Jadav, Dinesh M. Parmar · pp. 109–111Mini ReviewSame type: ArticleVolume 3
• Article · VOLUME 4, ISSUE 4Cabazitaxel: A novel taxane for metastatic castration‑resistant prostate cancer‑current implications and future prospectsAfroz Abidi · pp. 230–237Mini ReviewSame type: Article